PRDX4

Summary

PRDX4 (peroxiredoxin 4, HGNC:17169) is a protein-coding gene on chromosome Xp22.11, encoding Peroxiredoxin-4 (Q13162). Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.

The protein encoded by this gene is an antioxidant enzyme and belongs to the peroxiredoxin family. The protein is localized to the cytoplasm. Peroxidases of the peroxiredoxin family reduce hydrogen peroxide and alkyl hydroperoxides to water and alcohol with the use of reducing equivalents derived from thiol-containing donor molecules. This protein has been found to play a regulatory role in the activation of the transcription factor NF-kappaB.

Source: NCBI Gene 10549 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 87 total
• Regional missense constraint (gnomAD): 1 of 3 regions constrained (≈8% of expected missense variation)
• GTEx eGene: eQTL in 35 tissues, sQTL in 0 (q < 0.05)
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• MANE Select transcript: NM_006406
• Interaction hub: 2,358 STRING partners (top 5% of genes corpus-wide)
• Notable: 87 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17169
Approved symbol	PRDX4
Name	peroxiredoxin 4
Location	Xp22.11
Locus type	gene with protein product
Status	Approved
Aliases	AOE37-2
Ensembl gene	ENSG00000123131
Ensembl biotype	protein_coding
OMIM	300927
Entrez	10549

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 14 nonsense_mediated_decay, 11 protein_coding, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000379341

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 3: 3

ENST00000379341, ENST00000379331, ENST00000379349, ENST00000439422, ENST00000495599, ENST00000887283, ENST00000931168, ENST00000931169, ENST00000988484, ENST00000988485, ENST00000988486, ENST00000988487, ENST00000988489, ENST00001038760, ENST00001084463, ENST00001084470, ENST00001084471, ENST00001084474, ENST00001084476, ENST00001095693, ENST00001095694, ENST00001117752, ENST00001117753, ENST00001117754, ENST00001124129, ENST00001136491

RefSeq mRNA: 1 — MANE Select: NM_006406 NM_006406

CCDS: CCDS14206

Canonical transcript exons

ENST00000379341 — 7 exons

Exon	Start	End
ENSE00000836235	23682396	23682526
ENSE00000836236	23683671	23683705
ENSE00001828273	23686285	23686397
ENSE00001858070	23667493	23667811
ENSE00003495943	23671529	23671646
ENSE00003512837	23674990	23675106
ENSE00003789100	23679165	23679287

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 155.0809 / max 1791.9174, expressed in 1820 samples.

Highest expression (Bgee): body of pancreas, pancreas, tibia, adrenal tissue, islet of Langerhans.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PRDX4 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 35 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 35 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Muscle Skeletal	eqtl	2.5e-31	-0.34	X:23620988:A:G
Esophagus Muscularis	eqtl	1.1e-17	+0.34	X:23661817:A:T
Skin Sun Exposed Lower leg	eqtl	4.2e-17	+0.14	X:23666905:C:T
Nerve Tibial	eqtl	7.1e-15	+0.14	X:23666905:C:T
Artery Tibial	eqtl	1.4e-14	+0.12	X:23689710:G:A
Esophagus Mucosa	eqtl	1.5e-14	+0.14	X:23679368:G:A
Thyroid	eqtl	8.9e-12	+0.14	X:23681716:T:A
Brain Cerebellum	eqtl	2.1e-11	+0.30	X:23679368:G:A
Colon Sigmoid	eqtl	4.0e-11	+0.19	X:23681101:G:T
Colon Transverse	eqtl	1.4e-09	+0.12	X:23671242:A:G
Brain Hippocampus	eqtl	5.2e-08	+0.22	X:23683293:A:C
Brain Cerebellar Hemisphere	eqtl	7.2e-08	+0.19	X:23666450:G:A
Esophagus Gastroesophageal Junction	eqtl	6.7e-07	+0.26	X:23660381:C:CT
Adipose Subcutaneous	eqtl	1.9e-06	+0.12	X:23689710:G:A
Brain Frontal Cortex BA9	eqtl	4.8e-06	+0.20	X:23666450:G:A
Brain Spinal cord cervical c-1	eqtl	2.1e-05	+0.19	X:23679368:G:A
Cells Cultured fibroblasts	eqtl	2.7e-05	+0.07	X:23676359:A:T
Brain Nucleus accumbens basal ganglia	eqtl	3.1e-05	+0.17	X:23668070:C:T
Brain Anterior cingulate cortex BA24	eqtl	5.4e-05	+0.21	X:23666450:G:A
Lung	eqtl	9.9e-05	+0.06	X:23668070:C:T

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
195764	128.2859	1820
195765	26.7844	1787
195761	0.0106	4

Top tissues by expression

showing 100 of 295 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.47	gold quality
pancreas	UBERON:0001264	98.99	gold quality
tibia	UBERON:0000979	98.93	gold quality
adrenal tissue	UBERON:0018303	98.81	gold quality
islet of Langerhans	UBERON:0000006	98.62	gold quality
parotid gland	UBERON:0001831	98.52	gold quality
stromal cell of endometrium	CL:0002255	98.48	gold quality
type B pancreatic cell	CL:0000169	98.40	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	98.33	gold quality
right testis	UBERON:0004534	98.28	gold quality
left testis	UBERON:0004533	98.25	gold quality
adult organism	UBERON:0007023	98.20	gold quality
cartilage tissue	UBERON:0002418	98.17	gold quality
liver	UBERON:0002107	97.75	gold quality
decidua	UBERON:0002450	97.74	gold quality
periodontal ligament	UBERON:0008266	97.68	gold quality
testis	UBERON:0000473	97.67	gold quality
placenta	UBERON:0001987	97.53	gold quality
right lobe of liver	UBERON:0001114	97.50	gold quality
corpus epididymis	UBERON:0004359	97.49	gold quality
seminal vesicle	UBERON:0000998	97.40	gold quality
saliva-secreting gland	UBERON:0001044	97.19	gold quality
pituitary gland	UBERON:0000007	97.17	gold quality
ventricular zone	UBERON:0003053	97.11	gold quality
right atrium auricular region	UBERON:0006631	97.03	gold quality
endometrium	UBERON:0001295	97.02	gold quality
ascending aorta	UBERON:0001496	97.02	gold quality
thoracic aorta	UBERON:0001515	97.00	gold quality
minor salivary gland	UBERON:0001830	96.97	gold quality
adenohypophysis	UBERON:0002196	96.96	gold quality
cardiac atrium	UBERON:0002081	96.94	gold quality
right ovary	UBERON:0002118	96.83	gold quality
left coronary artery	UBERON:0001626	96.81	gold quality
gall bladder	UBERON:0002110	96.80	gold quality
descending thoracic aorta	UBERON:0002345	96.79	gold quality
trachea	UBERON:0003126	96.78	gold quality
smooth muscle tissue	UBERON:0001135	96.77	gold quality
skin of hip	UBERON:0001554	96.76	gold quality
right coronary artery	UBERON:0001625	96.76	gold quality
right adrenal gland	UBERON:0001233	96.75	gold quality
rectum	UBERON:0001052	96.73	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.70	gold quality
nasal cavity mucosa	UBERON:0001826	96.69	gold quality
oral cavity	UBERON:0000167	96.68	gold quality
coronary artery	UBERON:0001621	96.64	gold quality
peritoneum	UBERON:0002358	96.64	gold quality
omental fat pad	UBERON:0010414	96.64	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.63	gold quality
left adrenal gland	UBERON:0001234	96.62	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	96.60	gold quality
endocervix	UBERON:0000458	96.57	gold quality
body of stomach	UBERON:0001161	96.57	gold quality
left ovary	UBERON:0002119	96.57	gold quality
mouth mucosa	UBERON:0003729	96.57	gold quality
male germ cell	CL:0000015	96.53	gold quality
ovary	UBERON:0000992	96.52	gold quality
sperm	CL:0000019	96.47	gold quality
right adrenal gland cortex	UBERON:0035827	96.47	gold quality
left adrenal gland cortex	UBERON:0035825	96.38	gold quality
calcaneal tendon	UBERON:0003701	96.30	gold quality
adrenal gland	UBERON:0002369	96.28	gold quality
pigmented layer of retina	UBERON:0001782	96.26	gold quality
heart right ventricle	UBERON:0002080	96.24	gold quality
superficial temporal artery	UBERON:0001614	96.22	gold quality
uterus	UBERON:0000995	96.15	gold quality
adrenal cortex	UBERON:0001235	96.08	gold quality
ectocervix	UBERON:0012249	96.06	gold quality
layer of synovial tissue	UBERON:0007616	96.04	gold quality
synovial joint	UBERON:0002217	96.00	gold quality
caput epididymis	UBERON:0004358	95.94	gold quality
pericardium	UBERON:0002407	95.92	gold quality
aorta	UBERON:0000947	95.90	gold quality
adipose tissue	UBERON:0001013	95.89	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.89	gold quality
left uterine tube	UBERON:0001303	95.88	gold quality
stomach	UBERON:0000945	95.86	gold quality
parietal pleura	UBERON:0002400	95.86	gold quality
connective tissue	UBERON:0002384	95.82	gold quality
body of uterus	UBERON:0009853	95.78	gold quality
female reproductive system	UBERON:0000474	95.77	gold quality
pylorus	UBERON:0001166	95.76	gold quality
germinal epithelium of ovary	UBERON:0001304	95.75	gold quality
epithelium of nasopharynx	UBERON:0001951	95.72	gold quality
myocardium	UBERON:0002349	95.71	gold quality
thoracic mammary gland	UBERON:0005200	95.69	gold quality
right uterine tube	UBERON:0001302	95.68	gold quality
myometrium	UBERON:0001296	95.64	gold quality
mammary gland	UBERON:0001911	95.63	gold quality
embryo	UBERON:0000922	95.62	gold quality
bronchial epithelial cell	CL:0002328	95.53	gold quality
epithelial cell of pancreas	CL:0000083	95.50	gold quality
mucosa of transverse colon	UBERON:0004991	95.49	gold quality
tibial nerve	UBERON:0001323	95.46	gold quality
colonic mucosa	UBERON:0000317	95.44	gold quality
cardia of stomach	UBERON:0001162	95.44	gold quality
heart	UBERON:0000948	95.38	gold quality
cervix squamous epithelium	UBERON:0006922	95.38	gold quality
fundus of stomach	UBERON:0001160	95.27	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.25	gold quality
tibial artery	UBERON:0007610	95.13	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-HCAD-32	yes	1048.25
E-CURD-88	yes	131.52
E-HCAD-4	yes	69.01
E-HCAD-1	yes	64.28
E-MTAB-9467	yes	63.56
E-CURD-46	yes	61.46
E-CURD-122	yes	57.48
E-MTAB-8410	yes	42.04
E-HCAD-11	yes	26.28
E-HCAD-6	yes	18.08
E-CURD-112	yes	16.09
E-MTAB-10553	yes	15.64
E-MTAB-10042	yes	13.49
E-HCAD-31	no	21.20
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enriched

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Pancreas	tissue	1142.7	high
Liver	tissue	258.9	medium
Ovary	tissue	111.0	medium
Pituitary gland	tissue	95.6
Placenta	tissue	90.3	medium
Testis	tissue	89.5	high
Salivary gland	tissue	86.9	low
Cervix	tissue	77.3	medium
Stomach 1	tissue	76.9	medium
Rectum	tissue	73.9	low
Breast	tissue	70.0	medium
Colon	tissue	68.1	medium
Parathyroid gland	tissue	65.0	low
Urinary bladder	tissue	64.5	medium
Tonsil	tissue	62.9	low
Heart muscle	tissue	62.7	low
Fallopian tube	tissue	62.1	medium
Adipose tissue	tissue	60.8	medium
Gallbladder	tissue	60.6	medium
Duodenum	tissue	60.2	medium
Seminal vesicle	tissue	59.6	medium
Smooth muscle	tissue	58.7	low
Vagina	tissue	57.2	low
Prostate	tissue	56.2	low
Lymph node	tissue	55.0	medium
Adrenal gland	tissue	52.7	medium
Appendix	tissue	50.8	medium
Endometrium 1	tissue	49.6	medium
Small intestine	tissue	48.3	medium
Esophagus	tissue	46.2	low
Choroid plexus	tissue	45.4
Thyroid gland	tissue	43.0	medium
Frontal cortex	tissue	38.9
Kidney	tissue	37.5	low
Caudate putamen	tissue	36.7
Lung	tissue	34.3	medium
Skeletal muscle	tissue	32.6	medium
Bone marrow	tissue	32.3	low
Spleen	tissue	31.2	low
Skin 1	tissue	28.5	medium
Retina	tissue	27.9
Thymus	tissue	24.7
Tongue	tissue	23.6
Epididymis	tissue	18.4	medium
Locus coeruleus	tissue	16.5
Nucleus accumbens	tissue	15.7
Hippocampus	tissue	11.7	low
Cerebellum	tissue	10.8	low
Cerebral cortex	tissue	9.9	medium
Somatosensory cortex	tissue	9.9
Retrosplenial and cingulate cortex	tissue	9.8
Hippocampal formation	tissue	9.7
Entorhinal cortex	tissue	9.7
Temporal cortex	tissue	9.7
Prefrontal cortex	tissue	9.6
Occipital cortex	tissue	9.5
Insular cortex	tissue	9.3
Retrosplenial cortex	tissue	9.0
Corpus callosum	tissue	8.9
Motor cortex	tissue	8.8

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Blood vessel (97.4), Dorsal funiculus (white matter) (37.4), Lateral funiculus (white matter) (35.1), Anterior funiculus (white matter) (26.5), Nucleus raphe pallidus (25.7).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXO1, NRF1

Functional genomics

Regional missense constraint (gnomAD)

ENST00000379341 splits into 3 regions with different missense tolerance; 1 is missense-constrained (≈8% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
X:23,667,571–23,675,057	105 / 114.2	0.92	no
X:23,675,058–23,679,182	2 / 16.5	0.12	yes (p 3.5e-04)
X:23,679,183–23,686,332	73 / 76.5	0.95	no

Literature-anchored findings (GeneRIF, showing 40)

• 2-Cys Prxs act in a mutually nonredundant and sometimes stress-specific fashion to protect human cells from oxidant injury. The substantial resistance of human cells to hydroperoxides may result in part from the additive action of multiple Prxs (PMID:12080185)
• PRDX4 interacts with and regulates TBXA2R. (PMID:17644091)
• Peroxiredoxin IV forms complex structures within the ER, consistent with the formation of homodecamers (PMID:18052930)
• These results suggested that Prx IV involved in the 16alpha-OHE1-induced proliferation of MCF-7 cells has a proliferative effect and may be related to cancer development or progression. (PMID:18272409)
• data suggested that TRAIL suppressed the PRDX4 gene at the transcriptional level and that downregulation of PRDX4 might facilitate cell death induced by TRAIL (PMID:19364504)
• PRDX4 has a pivotal protective function against diabetes progression in this type 1 diabetes mellitus model (PMID:20446767)
• These results suggest that Prdx-1 and Prdx-4 are essential for preventing respiratory syncytial virus-induced oxidative damage in a subset of nuclear intermediate filament and actin binding proteins in epithelial cells. (PMID:20610706)
• PRDXs exhibit differential expression in prostate tumors, with PRDX3 and 4 consistently upregulated. (PMID:21031435)
• Here, the authors demonstrate that several members of the protein disulphide isomerase family are able to directly reduce this PrxIV disulphide and in the process become oxidized. (PMID:21057456)
• Elevated serum levels of the antioxidant Prx4 were associated with an increased disease severity and adverse outcome of critically ill patients with sepsis. (PMID:21283059)
• strong reduction in PRDX4 expression levels in APL correlates with increased trimethylation of histone 3 lysine residue 27 and 4 at the transcriptional start site of PRDX4, indicative of a bivalent histone code involved in transcriptional silencing. (PMID:21283726)
• Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment. (PMID:21487000)
• Data show that Keap1 and PRDX IV were overexpressed in the TNBC cohort. (PMID:21693047)
• A proteomic approach for identification and localization of the pericellular components of chondrocytes (PMID:21698479)
• Overexpression of PRDX4 and P4HA2 was significantly associated with lymphatic metastasis in oral cavity squamous cell carcinoma (PMID:21859152)
• This study solved crystal structures of human Prx4 in three different redox forms and characterized the reaction features of Prx4 with hydrogen peroxide. (PMID:21916849)
• Crystal structure of reduced and of oxidized peroxiredoxin IV enzyme reveals a stable oxidized decamer and a non-disulfide-bonded intermediate in the catalytic cycle (PMID:21994946)
• Prdx4 inhibits G-CSF-induced signalling and proliferation in myeloid progenitors. (PMID:22045733)
• A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. (PMID:22360420)
• Reverse phase protein arrays verified that the overexpression of both PRDX3 and PRDX4 in prostate tumor samples is negatively correlated with the presence of the TMPRSS2-ERG gene fusion. (PMID:22424448)
• data suggest that PRDX4 can be a novel target for glioblastoma multiforme therapies in the future (PMID:22916164)
• these results indicate that two placental proteins, Prx3 and Prx4, may act as new placental immune targets. Production of antibodies against peroxiredoxins 3 and 4 may introduce a new autoimmune hypothesis in recurrent pregnancy loss. (PMID:23190175)
• Elevated serum Prx4 levels are associated with a significantly higher risk of incident cardiovascular disease (CVD) events or CVD mortality and all-cause mortality after adjustment for clinical risk factors. (PMID:23316297)
• expression of Prxs I and IV, both at mRNA and protein levels, was associated with light chain secretion quantified by ELISA. (PMID:23737084)
• Remarkably, the Prx4-dependent formation of native disulfide bonds was accelerated when PDI was combined with ERp46 or P5, suggesting that PDIs work synergistically to increase the rate and fidelity of oxidative protein folding. (PMID:23949117)
• Data indicate that protein disulfide isomerase (PDI) and ERp44 dynamically localize Ero1alpha and peroxiredoxin 4 in early secretory compartment (ESC). (PMID:23979138)
• expression of PRDX4 in PCOS ovaries appeared to be mediated through oxidative stress in GCs. We reported that the deficiency of antioxidant PRDX4 was associated with pathophysiological mechanism of PCOS. (PMID:24098506)
• peroxiredoxin IV recycling in the endoplasmic reticulum is much less efficient than in the cytosol or mitochondria, leading to the protection of peroxiredoxin IV from hyperoxidation. (PMID:24403061)
• The structure and function of PRDX4 as well as its sensitivity to hyperoxidation. [Review] (PMID:24450625)
• Prx4 is a circulating antioxidant and is independently associated with increased risk of cardiovascular and all-cause mortality in T2DM. (PMID:24586984)
• there is a significant difference in concentration of Prx4 between cardiac arrest patients with good and poor outcome (PMID:24617620)
• Findings suggest that elevated serum Prx4 levels are associated with a higher risk of incident type 2 diabetes (PMID:24893865)
• these data suggest an important role of Prdx4 in maintaining insulin levels and improving the ER folding capacity also under conditions of a high insulin requirement. (PMID:25122762)
• An off-pathway reaction in the Prx4-mediated oxidative protein folding. (PMID:25137134)
• Positive Prx 4 expression is significantly correlated with recurrence and shorter disease-free survival in patients with early-stage lung squamous cell carcinoma. (PMID:26261544)
• Prdx4 expression was closely related to follicular development and has aprominent role in protecting human and mouse granulosa cells from reactive oxygen species damage. (PMID:26917265)
• levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. (PMID:27303935)
• Results show that ERp44 binds the oxidized but not the reduced form of Prx4; the ERp44-Prx4 complex is formed via thiol-disulfide interchange reactions, and its crystal structure reveals a redox-dependent recognition. (PMID:27642162)
• Significant reduction in mRNA and protein levels of PrdxIV was observed in HEK293 cells overexpressing pathologically relevant recombinant mutant GNE protein (D207V and V603L) compared with vector control. Downregulation of PrdxIV keep the ER in a reduced (redox) state that may contribute to misfolding and aggregation of proteins in GNE myopathy. (PMID:28895049)
• Hepatocellular carcinoma (HCC) tumors with low expression of PRDX4 had higher ROS levels, malignancy, and associated with reduced overall survival. In HCC cell lines, its knockdown led to increased intracellular ROS level and suppressed cell proliferation, inducing cell death. These results indicate that PRDX4 has an inhibitory effect in the initiation of HCC, but a dual (inhibitory or promoting) role in the progression. (PMID:29687726)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	prdx4	ENSDARG00000069013
mus_musculus	Prdx4	ENSMUSG00000025289
rattus_norvegicus	Prdx4	ENSRNOG00000003763
drosophila_melanogaster	Prx4	FBGN0040308
caenorhabditis_elegans		WBGENE00011110

Paralogs (4): PRDX1 (ENSG00000117450), PRDX6 (ENSG00000117592), PRDX3 (ENSG00000165672), PRDX2 (ENSG00000167815)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1859815) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 5 distinct phenotype terms.

Mouse phenotype (MP)	Records
oligozoospermia	1
testicular atrophy	1
oxidative stress	1
decreased testis weight	1
increased male germ cell apoptosis	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Staphylococcus aureus subsp. aureus Mu50	P0A0B5	100.0%	Diamond
Staphylococcus aureus subsp. aureus MW2	P0A0B6	100.0%	Diamond
Staphylococcus aureus subsp. aureus NCTC 8325	P0A0B7	100.0%	Diamond
Salmonella enterica subsp. enterica serovar Typhimurium str. LT2	P0A251	100.0%	Diamond
Salmonella enterica subsp. enterica serovar Typhi	P0A252	100.0%	Diamond
Escherichia coli K-12	P0AE08	100.0%	Diamond
Escherichia coli CFT073	P0AE09	100.0%	Diamond
Escherichia coli O157:H7	P0AE10	100.0%	Diamond
Shigella flexneri	P0AE11	100.0%	Diamond
Candida albicans SC5314	P0CU34	100.0%	Diamond
Mycobacterium tuberculosis variant bovis AF2122/97	P65689	100.0%	Diamond
Staphylococcus aureus subsp. aureus N315	P99074	100.0%	Diamond
Mycobacterium tuberculosis CDC1551	P9WIE0	100.0%	Diamond
Mycobacterium tuberculosis H37Rv	P9WIE1	100.0%	Diamond
Staphylococcus aureus subsp. aureus USA300	Q2FJN4	100.0%	Diamond
Macaca fascicularis	Q2PFZ3	100.0%	Diamond
Staphylococcus aureus RF122	Q2YVK2	100.0%	Diamond
Staphylococcus aureus subsp. aureus COL	Q5HIR5	100.0%	Diamond
Staphylococcus aureus subsp. aureus MSSA476	Q6GC91	100.0%	Diamond
Staphylococcus aureus subsp. aureus MRSA252	Q6GJR7	100.0%	Diamond
Triticum aestivum	P80602	99.5%	Diamond
Staphylococcus epidermidis RP62A	Q5HRY1	99.5%	Diamond
Staphylococcus epidermidis ATCC 12228	Q8CMQ2	99.5%	Diamond
Hordeum vulgare	Q96468	99.5%	Diamond
Pongo abelii	Q5RC63	99.4%	Diamond
Myotis lucifugus	Q6B4U9	99.0%	Diamond
Spinacia oleracea	O24364	98.5%	Diamond
Helicobacter pylori 26695	P21762	98.5%	Diamond
Helicobacter pylori J99	P56876	98.5%	Diamond
Arabidopsis thaliana	Q96291	98.5%	Diamond
Methanococcus maripaludis C5	A4FWZ9	97.2%	Diamond
Thermotoga petrophila RKU-1	A5IIX7	97.2%	Diamond
Methanococcus maripaludis S2	Q6LY19	97.2%	Diamond
Thermotoga maritima MSB8	Q9WZR4	97.2%	Diamond
Bos taurus	Q5E947	97.0%	Diamond
Cricetulus griseus	Q8K3U7	96.5%	Diamond
Methanothermobacter thermautotrophicus str. Delta H	O26262	95.7%	Diamond
Methanothermobacter marburgensis str. Marburg	Q57109	95.7%	Diamond
Pyrococcus abyssi GE5	Q9UZV4	94.4%	Diamond
Pyrococcus horikoshii OT3	O58966	94.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PTCHD1-AS	ncRNA	100873065
PTCHD1	protein-coding	139411
ACOT9	protein-coding	23597
SAT1	protein-coding	6303
APOO	protein-coding	79135
SAT1-DT	ncRNA	105373148
CXorf58	protein-coding	254158

Protein

Protein identifiers

Peroxiredoxin-4 — Q13162 (reviewed: Q13162)

Alternative names: Antioxidant enzyme AOE372, Peroxiredoxin IV, Thioredoxin peroxidase AO372, Thioredoxin-dependent peroxide reductase A0372, Thioredoxin-dependent peroxiredoxin 4

All UniProt accessions (5): A6NG45, A6NJJ0, H7C3T4, Q13162, V9HW63

UniProt curated annotations — full annotation on UniProt →

Function. Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Regulates the activation of NF-kappa-B in the cytosol by a modulation of I-kappa-B-alpha phosphorylation.

Subunit / interactions. Homodimer; disulfide-linked, upon oxidation. 5 homodimers assemble to form a ring-like decamer. Can form heterodimers with PRDX1.

Subcellular location. Cytoplasm. Endoplasmic reticulum.

Post-translational modifications. The enzyme can be inactivated by further oxidation of the cysteine sulfenic acid (C(P)-SOH) to sulphinic acid (C(P)-SO2H) and sulphonic acid (C(P)-SO3H) instead of its condensation to a disulfide bond.

Miscellaneous. The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin.

Similarity. Belongs to the peroxiredoxin family. AhpC/Prx1 subfamily.

RefSeq proteins (1): NP_006397* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000866	AhpC/TSA	Domain
IPR013766	Thioredoxin_domain	Domain
IPR019479	Peroxiredoxin_C	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR050217	Peroxiredoxin	Family

Pfam: PF00578, PF10417

Enzyme classification (BRENDA)

• EC 1.11.1.24 — thioredoxin-dependent peroxiredoxin (BRENDA: 72 organisms, 110 substrates, 31 inhibitors, 72 Km, 50 kcat entries)

Substrate kinetics (BRENDA)

13 substrates with measured Km, best-characterized 13. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
H2O2	0.0004–11.7	23
CUMENE HYDROPEROXIDE	0.0066–0.191	8
THIOREDOXIN	0.001–0.0794	7
TERT-BUTYL HYDROPEROXIDE	—	5
THIOREDOXIN A	0.0009–0.0122	5
THIOREDOXIN B	0.0022–0.0208	5
T-BUTYL HYDROPEROXIDE	0.072–0.193	4
THIOREDOXIN Q	0.0007–0.0028	4
REDUCED THIOREDOXIN	0.0024–0.004	2
REDUCED THIOREDOXIN A	0.0079–0.0087	2
ETHYL HYDROPEROXIDE	0.0045	1
LINOLEIC ACID HYDROPEROXIDE	0.117	1
TRYPAREDOXIN 2	0.0319	1

Catalyzed reactions (Rhea)

• a hydroperoxide + [thioredoxin]-dithiol = an alcohol + [thioredoxin]-disulfide + H2O (RHEA:62620)

UniProt features (33 total): strand 12, helix 9, turn 4, disulfide bond 2, sequence conflict 2, signal peptide 1, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

14 structures by resolution:

PDB	Title	Method	Resolution (Å)
2PN8	Crystal structure of human peroxiredoxin 4 (thioredoxin peroxidase)	X-RAY DIFFRACTION	1.8
3TJJ	Crystal structure of human peroxiredoxin IV C245A mutant in sulfenylated form	X-RAY DIFFRACTION	1.91
3TJF	Crystal Structure of human peroxiredoxin IV C51A mutant in reduced form	X-RAY DIFFRACTION	2.04
3TJK	Crystal Structure of human peroxiredoxin IV C245A mutant in reduced form	X-RAY DIFFRACTION	2.09
3TKR	Crystal structure of full-length human peroxiredoxin 4 with T118E mutation	X-RAY DIFFRACTION	2.1
3TKQ	Crystal structure of full-length human peroxiredoxin 4 with mixed conformation	X-RAY DIFFRACTION	2.22
3TJG	Crystal Structure of human peroxiredoxin IV C51A mutant in oxidized form	X-RAY DIFFRACTION	2.24
4RQX	Crystal structure of human peroxiredoxin 4(THIOREDOXIN PEROXIDASE) with MESNA	X-RAY DIFFRACTION	2.26
3TJB	Crystal structure of wild-type human peroxiredoxin IV	X-RAY DIFFRACTION	2.38
3TKS	Crystal structure of full-length human peroxiredoxin 4 in three different redox states	X-RAY DIFFRACTION	2.4
3TKP	Crystal structure of full-length human peroxiredoxin 4 in the reduced form	X-RAY DIFFRACTION	2.49
5HQP	Crystal structure of the ERp44-peroxiredoxin 4 complex	X-RAY DIFFRACTION	2.6
8EKW	Cryo-EM structure of human PRDX4	ELECTRON MICROSCOPY	2.83
8EKY	Cryo-EM structure of the human PRDX4-ErP46 complex	ELECTRON MICROSCOPY	3.47

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13162-F1	84.59	0.72

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Predicted intracellular proteins, Cancer-related genes, Candidate cancer biomarkers

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): endoplasmic reticulum; cytosol

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
124	cysteine sulfenic acid (-soh) intermediate

Disulfide bonds (2)

Type	Positions
Interchain (with c-245)	124
Interchain (with c-124)	245

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—

MSigDB gene sets: 302 (showing top): MODULE_93, GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GRUETZMANN_PANCREATIC_CANCER_DN, BASSO_B_LYMPHOCYTE_NETWORK, GOCC_SECRETORY_GRANULE, MODULE_151, GOBP_HYDROGEN_PEROXIDE_CATABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, KYNG_DNA_DAMAGE_DN, GOBP_MALE_GAMETE_GENERATION, CEBPB_01

GO Biological Process (5): response to oxidative stress (GO:0006979), I-kappaB phosphorylation (GO:0007252), hydrogen peroxide catabolic process (GO:0042744), cell redox homeostasis (GO:0045454), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (10): thioredoxin peroxidase activity (GO:0008379), identical protein binding (GO:0042802), molecular adaptor activity (GO:0060090), molecular sequestering activity (GO:0140313), peroxidase activity (GO:0004601), protein binding (GO:0005515), antioxidant activity (GO:0016209), oxidoreductase activity (GO:0016491), peroxiredoxin activity (GO:0051920), thioredoxin-dependent peroxiredoxin activity (GO:0140824)

GO Cellular Component (8): extracellular region (GO:0005576), nucleus (GO:0005634), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), secretory granule lumen (GO:0034774), extracellular exosome (GO:0070062), ficolin-1-rich granule lumen (GO:1904813), cytoplasm (GO:0005737)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Innate Immune System	1
Immune System	1

GO top-level categories

27 GO namespaces:

Category	Terms
molecular_function	3
cellular anatomical structure	3
binding	2
intracellular membrane-bounded organelle	2
cytoplasm	2
response to stress	1
protein phosphorylation	1
canonical NF-kappaB signal transduction	1
catabolic process	1
hydrogen peroxide metabolic process	1
cellular homeostasis	1
cellular detoxification	1
thioredoxin-dependent peroxiredoxin activity	1
protein binding	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
cellular oxidant detoxification	1
catalytic activity	1
peroxidase activity	1
peroxiredoxin activity	1
endomembrane system	1
secretory granule	1
cytoplasmic vesicle lumen	1
extracellular vesicle	1
intracellular organelle lumen	1
ficolin-1-rich granule	1
intracellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 23 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
cytosol	CC	direct assay
endoplasmic reticulum	CC	direct assay
extracellular exosome	CC	high-throughput assay
nucleus	CC	high-throughput assay
molecular adaptor activity	MF	experiment
molecular sequestering activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 2,358 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRDX4	GLUL	P15104	782
PRDX4	PRDX5	P30044	753
PRDX4	TXN	P10599	696
PRDX4	SRXN1	Q9BYN0	639
PRDX4	GPX7	Q96SL4	638
PRDX4	GPX8	Q8TED1	630
PRDX4	ERO1A	Q96HE7	618
PRDX4	TXNDC5	Q8NBS9	574
PRDX4	TXNRD1	Q16881	563
PRDX4	GPX4	P36969	553
PRDX4	ERO1B	Q86YB8	550
PRDX4	GLRX	P35754	550
PRDX4	ERP44	Q9BS26	539
PRDX4	TXN2	Q99757	537
PRDX4	P4HB	P07237	531

IntAct

Human interaction partners of PRDX4 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

28 partners by confidence:

Partner	Interaction type	MIscore	Records
ATXN1	physical association	0.670	3
LBP	physical association	0.600	4
TBXA2R	physical association	0.590	3
PRDX1	physical association	0.570	2
NR4A1	physical association	0.550	2
PDIA6	oxidoreductase activity electron transfer reaction	0.520	2
P4HB	oxidoreductase activity electron transfer reaction	0.440	2
PDIA3	oxidoreductase activity electron transfer reaction	0.440	2
TXNDC5	oxidoreductase activity electron transfer reaction	0.440	2
A1BG	physical association	0.370	1
ALG12	physical association	0.370	1
APOB	physical association	0.370	1
CFHR1	physical association	0.370	1
CFHR3	physical association	0.370	1
CLIC1	physical association	0.370	1
CYP27A1	physical association	0.370	1
DUSP23	physical association	0.370	1
EP300	physical association	0.370	1
HDAC6	physical association	0.370	1
MAP4K2	physical association	0.370	1
MT-CO1	physical association	0.370	1
PLG	physical association	0.370	1
PRDX2	physical association	0.370	1
PRDX3	physical association	0.370	1
RCHY1	physical association	0.370	1
SULT2A1	physical association	0.370	1
TTF2	physical association	0.370	1
VTN	physical association	0.370	1

BioGRID (314 interactions; top human partners by supporting records): PRDX1 (Two-hybrid; 11 records), AGR2 (Proximity Label-MS; 4 records), OTUD1 (Proximity Label-MS; 4 records), CUL3 (Affinity Capture-MS; 3 records), INS (Affinity Capture-MS; 3 records), TBXA2R (Two-hybrid; 3 records), AURKA (Affinity Capture-MS; 2 records), CCNF (Affinity Capture-MS; 2 records), CLIC1 (Affinity Capture-MS; 2 records), CTSB (Affinity Capture-MS; 2 records), CTSS (Affinity Capture-MS; 2 records), DPP4 (Affinity Capture-MS; 2 records), HDAC6 (Affinity Capture-MS; 2 records), HSPA5 (Affinity Capture-Western; 2 records), HUWE1 (Affinity Capture-MS; 2 records)

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
protein folding	5	18.5×	2e-03

Disease & clinical

Genetic variants

Variant evidence for PRDX4: 87 ClinVar records (0 pathogenic / likely pathogenic); 1 PharmGKB clinical annotation.

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	24
Likely benign	0
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 33 predictions of 440):

Position(s)	Effect	Δscore	Sites
X:23671647–23671648	donor_loss	1.0000	5
X:23674988–23674989	acceptor_loss	1.0000	6
X:23675107–23675108	donor_loss	1.0000	5
X:23682386	acceptor_gain	1.0000
X:23682393	acceptor_gain	1.0000
X:23682394–23682395	acceptor_loss	1.0000	5
X:23682524	donor_gain	1.0000
X:23682527–23682528	donor_loss	1.0000	4
X:23683659	acceptor_gain	1.0000
X:23683706–23683707	donor_loss	1.0000	4

AlphaMissense

895 missense substitutions predicted likely pathogenic (of 1,730 scored), across 186 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D151	8	0.997	0.999
D179	8	0.996	0.999
H156	8	0.994	0.999
D218	8	0.993	0.998
D119	8	0.988	0.997
F122	8	0.988	1.000
F120	8	0.986	1.000
F115	8	0.976	0.998
F138	8	0.976	0.999
F267	8	0.976	0.995
F131	8	0.963	0.997
F203	8	0.958	0.998
N217	8	0.951	0.999
F235	8	0.942	0.996
D206	8	0.940	0.997
F98	8	0.920	0.996
H197	8	0.865	0.985
D239	8	0.860	0.971
D226	8	0.818	0.963
F113	8	0.811	0.994

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

6 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Papillary Cell Carcinoma (TCGA)	unfavorable	2.37e-07
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	7.58e-06
Bladder Urothelial Carcinoma (TCGA)	unfavorable	9e-05
Kidney Chromophobe (TCGA)	unfavorable	0.000291
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	0.000553
Breast Invasive Carcinoma (TCGA)	unfavorable	0.000809

Disease associations

OMIM: gene MIM:300927 | disease phenotypes:

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295812 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,601 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,601

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

1 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs518329	Dosage	3	docetaxel	Non-Small Cell Lung Carcinoma

PharmGKB variants

1 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs518329	PRDX4	3	0.25	1	docetaxel

Binding affinities (BindingDB)

2 measured of 2 human assays (4 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5565154	IC50	350 nM
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.52	Kd	30.49	nM	CHEMBL5653589
7.52	ED50	30.49	nM	CHEMBL5653589
5.56	Kd	2733	nM	CHEMBL3752910
5.56	ED50	2733	nM	CHEMBL3752910
5.00	IC50	1e+04	nM	MOLIBRESIB

PubChem BioAssay actives

3 with measured affinity, of 17 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149064: Binding affinity to human PRDX4 incubated for 45 mins by Kinobead based pull down assay	kd	0.0305	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149064: Binding affinity to human PRDX4 incubated for 45 mins by Kinobead based pull down assay	kd	2.7330	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178893: Inhibition of PRDX4 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	10.0000	uM

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	5
bisphenol A	affects expression, decreases expression, increases expression	3
Tobacco Smoke Pollution	affects expression, increases expression	3
Aerosols	decreases expression, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Cadmium	decreases expression, increases abundance, increases expression	2
Doxorubicin	affects expression, increases expression	2
Hydrogen Peroxide	affects cotreatment, increases expression	2
Valproic Acid	affects expression, increases expression	2
Cyclosporine	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
moringin	affects cotreatment, decreases expression	1
methylmercuric chloride	increases expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
16-hydroxyestrone	increases expression	1
gallium nitrate	decreases expression	1
gossypol acetic acid	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
dibenzo(a,l)pyrene	decreases expression	1
cyfluthrin	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CD 437	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
chromium histidinate	increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

11 unique, capped per target: 11 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118781	Binding	Binding affinity to PRDX4 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — *Bioorg Med Chem*

Cellosaurus cell lines

6 cell lines: 5 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3ET	Abcam HEK293T PRDX4 KO	Transformed cell line	Female
CVCL_E2HK	HAP1 PRDX4 (-) 1	Cancer cell line	Male
CVCL_E2HL	HAP1 PRDX4 (-) 2	Cancer cell line	Male
CVCL_E2HM	HAP1 PRDX4 (-) 3	Cancer cell line	Male
CVCL_E2HN	HAP1 PRDX4 (-) 4	Cancer cell line	Male
CVCL_E2HP	HAP1 PRDX4 (-) 5	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PRDX4 across ~30M SureChEMBL compounds — explore on Sugi Predict.